Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

UroGen Pharma (URGN) Operating Margin: 2017-2025

Historic Operating Margin for UroGen Pharma (URGN) over the last 7 years, with Sep 2025 value amounting to -99.65%.

  • UroGen Pharma's Operating Margin fell 3004.00% to -99.65% in Q3 2025 from the same period last year, while for Sep 2025 it was -138.22%, marking a year-over-year decrease of 4452.00%. This contributed to the annual value of -107.06% for FY2024, which is 2783.00% down from last year.
  • Per UroGen Pharma's latest filing, its Operating Margin stood at -99.65% for Q3 2025, which was up 41.78% from -171.17% recorded in Q2 2025.
  • In the past 5 years, UroGen Pharma's Operating Margin registered a high of -62.09% during Q4 2023, and its lowest value of -348.88% during Q1 2021.
  • Its 3-year average for Operating Margin is -110.77%, with a median of -112.59% in 2024.
  • Per our database at Business Quant, UroGen Pharma's Operating Margin soared by 63,499bps in 2021 and then tumbled by 5,290bps in 2025.
  • UroGen Pharma's Operating Margin (Quarterly) stood at -123.13% in 2021, then soared by 1,102bps to -112.10% in 2022, then spiked by 5,002bps to -62.09% in 2023, then plummeted by 5,050bps to -112.59% in 2024, then slumped by 3,004bps to -99.65% in 2025.
  • Its Operating Margin was -99.65% in Q3 2025, compared to -171.17% in Q2 2025 and -182.26% in Q1 2025.